Clinical trials are critical to advancing research. They are the only way to bring potential new therapies forward to help people living with diseases.
Synlogic clinical trials underway are listed below.
Synlogic is conducting a clinical research study to evaluate a potential new treatment option for PKU. This is the third clinical study for this potential treatment and it is currently accepting new patients, aged 18 years and older. The study is open to people with PKU who are currently taking sapropterin (also known as Kuvan) as well as those who are not currently taking a drug treatment.
For more information about the study and to see if you may participate visit https://pkuresearchstudy.com.
Enteric Hyperoxaluria Trial
Enteric Hyperoxaluria (HOX) is a well-known complication of multiple bowel conditions, including inflammatory bowel diseases, bariatric/weight-loss surgery, short bowel syndrome, and others. The disorder, which is caused by the over-absorption of oxalate in the GI tract, results in dangerously high urinary oxalate levels, damaging the kidneys. Recurrent kidney stones, chronic kidney disease, and nephrocalcinosis (hardening of the kidney due to toxic calcium oxalate crystal deposits) may result. There are currently no approved therapies for Enteric Hyperoxaluria. SYNB8802 is an oral investigational Synthetic Biotic medicine designed to break down oxalate in the GI tract, lower levels of oxalate in the urine, and potentially reduce the risk for related kidney damage.
Synlogic is conducting a Phase 1a/b clinical study to evaluate the safety, tolerability, and potential for urinary oxalate lowering of SYNB8802 in healthy volunteers and patients. The study has two parts: Part A is a multiple ascending dose study in healthy volunteers; Part B is a placebo controlled, cross-over design study in patients with Enteric Hyperoxaluria following Roux-en-Y gastric bypass surgery.
To date, we have demonstrated that SYNB8802 has achieved proof of mechanism in healthy volunteers during Part A of the study. Now, Synlogic has initiated Part B of the study in patients with Enteric Hyperoxaluria following Roux-en-Y gastric bypass surgery. For more information about the study (NCT04629170) and potential participation, click here.